GetTopicDetailResponse(id=1bf328e05e0, topicName=先導(dǎo)化合物, introduction=先導(dǎo)化合物, content=null, image=null, comments=3, allHits=1728, url=https://h5.medsci.cn/topic?id=28705, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=3990, tagList=[TagDto(tagId=3990, tagName=先導(dǎo)化合物)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2168991, encodeId=0c112168991bd, content=<a href='/topic/show?id=466e159032f' target=_blank style='color:#2F92EE;'>#SARS-COV-2#</a> <a href='/topic/show?id=c21f10e47464' target=_blank style='color:#2F92EE;'>#主蛋白酶#</a> <a href='/topic/show?id=1bf328e05e0' target=_blank style='color:#2F92EE;'>#先導(dǎo)化合物#</a>, objectTitle=Science：發(fā)現(xiàn)一系列針對 SARS-CoV-2的強(qiáng)效抗病毒氨基吡啶先導(dǎo)化合物, objectType=article, longId=800385, objectId=0b2b800385bc, topicUrl=null, isHasObj=0, objectCover=https://msimg.bioon.com/bioon-com/20231111/1699661862046_2185383.png, objectUrl=/article/show_article.do?id=0b2b800385bc, replyNumber=0, likeNumber=111, createdTime=2023-11-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2098410, encodeId=4ca82098410a9, content=IHCH-7086和IHCH-7079為代表的一系列<a href='/topic/show?id=fd9210499218' target=_blank style='color:#2F92EE;'>#5-HT2AR#</a>的β-arrestin信號偏好性激動劑的<a href='/topic/show?id=1bf328e05e0' target=_blank style='color:#2F92EE;'>#先導(dǎo)化合物#</a>；并在動物體內(nèi)實(shí)驗(yàn)中證明該系列化合物無<a href='/topic/show?id=7a27104988d3' target=_blank style='color:#2F92EE;'>#致幻#</a>作用，但具備與致幻劑相似的快速<a href='/topic/show?id=7999553333c' target=_blank style='color:#2F92EE;'>#抗抑郁#</a>效果。, objectTitle=Science：中國科學(xué)家團(tuán)隊(duì)研發(fā)出新型快速抗抑郁化合物, objectType=article, longId=294869, objectId=b50029486921, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/1a9e2158737cd58e4.jpg, objectUrl=/article/show_article.do?id=b50029486921, replyNumber=0, likeNumber=183, createdTime=2022-11-04, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b50029486921, moduleTitle=Science：中國科學(xué)家團(tuán)隊(duì)研發(fā)出新型快速抗抑郁化合物, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b50029486921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2098404, encodeId=531720984049b, content=<a href='/topic/show?id=ceb610498584' target=_blank style='color:#2F92EE;'>#ZZL-7#</a><a href='/topic/show?id=1bf328e05e0' target=_blank style='color:#2F92EE;'>#先導(dǎo)化合物#</a><a href='/topic/show?id=0a0b5496306' target=_blank style='color:#2F92EE;'>#抑郁#</a>十分有前途, objectTitle=Science：我國學(xué)者發(fā)現(xiàn)抑郁癥全新靶點(diǎn)及候選藥物，2小時(shí)快速起效且無副作用, objectType=article, longId=745898, objectId=508ae4589897, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/095.jpg, objectUrl=/article/show_article.do?id=508ae4589897, replyNumber=0, likeNumber=137, createdTime=2022-11-04, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508ae4589897, moduleTitle=Science：我國學(xué)者發(fā)現(xiàn)抑郁癥全新靶點(diǎn)及候選藥物，2小時(shí)快速起效且無副作用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=508ae4589897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2098403, encodeId=b5c92098403e2, content=<a href='/topic/show?id=ca4e10499055' target=_blank style='color:#2F92EE;'>#Hesperadin#</a> 具有<a href='/topic/show?id=25075141959' target=_blank style='color:#2F92EE;'>#心臟保護(hù)#</a>和抗腫瘤雙重作用，不僅表明 Hesperadin 是臨床治療心臟I/R損傷和<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>的一種有前景的<a href='/topic/show?id=1bf328e05e0' target=_blank style='color:#2F92EE;'>#先導(dǎo)化合物#</a>，而且為<a href='/topic/show?id=5cd15549658' target=_blank style='color:#2F92EE;'>#抗癌#</a>治療時(shí)引起心臟毒性，進(jìn)而導(dǎo)致<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌癥#</a>和<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病的聯(lián)合治療提供了新策略。, objectTitle=Circulation：張巖/雷曉光合作發(fā)現(xiàn)治療心臟損傷候選藥物分子, objectType=article, longId=724368, objectId=68e8e2436817, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220415/1650023179241_5295905.jpg, objectUrl=/article/show_article.do?id=68e8e2436817, replyNumber=0, likeNumber=220, createdTime=2022-11-04, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68e8e2436817, moduleTitle=Circulation：張巖/雷曉光合作發(fā)現(xiàn)治療心臟損傷候選藥物分子, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=68e8e2436817)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
